Article
Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
The Journal of pathology - 1 Nov 2017
Noh Ka-Won, Lee Mi-Sook, Lee Seung Eun, Song Ji-Young, Shin Hyun-Tae, Kim Yu Jin, Oh Doo Yi, Jung Kyungsoo, Sung Minjung, Kim Mingi, An Sungbin, Han Joungho, Shim Young Mog, Zo Jae Ill, Kim Jhingook, Park Woong-Yang, Lee Se-Hoon, Choi Yoon-La
Abstract excerpt
Most anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancers (NSCLCs) show good clinical response to ALK inhibitors. However, some ALK-rearranged NSCLC patients show various primary responses with unknown reasons. Previous studies focused on the clinical aspects of ALK fusions in small cohorts, or were conducted in vitro and/or in vivo to investigate the function of ALK. One of the suggested...
Topics
- Adult
- Aged
- Aged, 80 and over
- Anaplastic Lymphoma Kinase
- Carcinoma, Non-Small-Cell Lung
- Female
- Humans
- Lung Neoplasms
- Male
- Microtubule-Associated Proteins